Impact of clopidogrel treatment on platelet function and thrombogenecity in diabetic patients undergoing elective coronary stenting

High platelet reactivity (HPR) and suboptimal response to dual antiplatelet therapy (DAPT) may explain high recurrent rates of ischemic events in Type II diabetes mellitus (DM) patients undergoing percutaneous coronary intervention (PCI). The aim of this study was to examine the effect of clopidogrel on platelet reactivity, and thrombogenecity between DM and non-DM PCI-treated patients (n = 138). Patients were categorized according to clopidogrel treatment and DM status. Patients received a maintenance-dose clopidogrel of 75 mg/d (C75 group, n = 72) or a 600 mg clopidogrel loading-dose in clopidogrel na?ve patients (C600 group, n = 66). Platelet function was assessed by thrombelastography, flow cytometry, VerifyNowTM aspirin assay and light transmittance aggregometry (LTA). Aspirin response was similar between treatments and DM status. In the C75 group, DM patients had higher 5 and 20 μM ADP-, 2 μg/ml collagen-induced LTA; and p-selectin expression compared to non-DM patients (p ≤ 0.05 for all). DM patients in the C600 group had higher 5 and 20 μM ADP-induced LTA post dosing (p p 12 receptor antagonists.

[1]  K. Mann,et al.  Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography , 2005, Journal of thrombosis and haemostasis : JTH.

[2]  R. Califf,et al.  2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.

[3]  J. García-Mena,et al.  Association of CYP2C19 genotype with type 2 diabetes. , 2010 .

[4]  M. Leon,et al.  The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.

[5]  D. Schneider.  Factors Contributing to Increased Platelet Reactivity in People With Diabetes , 2009, Diabetes Care.

[6]  R. Nesto,et al.  The platelet in diabetes: focus on prevention of ischemic events. , 2003, Diabetes care.

[7]  O. Morel,et al.  Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. , 2011, Atherosclerosis.

[8]  U. Rauch,et al.  Clopidogrel‐mediated reduction of circulating tissue factor in patients with stable coronary artery disease , 2007, European journal of haematology.

[9]  W. Herzog,et al.  The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. , 2005, Journal of the American College of Cardiology.

[10]  E. D. Lorenzo,et al.  Impact of diabetes on long-term outcome in STEMI patients undergoing primary angioplasty with glycoprotein IIb–IIIa inhibitors and BMS or DES , 2010, Journal of Thrombosis and Thrombolysis.

[11]  V. Pasceri,et al.  Clopidogrel reloading in patients undergoing percutaneous coronary intervention on chronic clopidogrel therapy: results of the ARMYDA-4 RELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. , 2010, European heart journal.

[12]  W. Weintraub,et al.  Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. , 1995, Circulation.

[13]  J. Akkerman,et al.  Platelet Inhibition by Insulin Is Absent in Type 2 Diabetes Mellitus , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[14]  P. Zimmet,et al.  Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[15]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[16]  C. Macaya,et al.  Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. , 2005, Diabetes.

[17]  E. Liu,et al.  Dissecting the Activation of Thienopyridines by Cytochromes P450 Using a Pharmacodynamic Assay In Vitro , 2011, Journal of Pharmacology and Experimental Therapeutics.

[18]  A. Siegbahn,et al.  Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. , 2008, Journal of the American College of Cardiology.

[19]  O. Muller,et al.  Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. , 2010, The American journal of cardiology.

[20]  T. Geisler,et al.  Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions , 2010, Clinical Research in Cardiology.

[21]  P. Gurbel,et al.  The Effect of Aspirin Dosing on Platelet Function in Diabetic and Nondiabetic Patients , 2007, Diabetes.

[22]  Jeffrey L. Anderson,et al.  2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[23]  S. Goto,et al.  A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. , 2008, European heart journal.

[24]  P. Grant,et al.  Inflammation and thrombosis in diabetes , 2011, Thrombosis and Haemostasis.

[25]  J. Muhlestein.  Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients , 2009, Thrombosis and Haemostasis.

[26]  I. Russo,et al.  Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. , 2008, Current vascular pharmacology.

[27]  Yi Li,et al.  Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. , 2009, American heart journal.

[28]  J. Akkerman,et al.  IRS-1 Mediates Inhibition of Ca2+ Mobilization by Insulin via the Inhibitory G-protein Gi* , 2004, Journal of Biological Chemistry.

[29]  O. Morel,et al.  Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis. , 2010, Atherosclerosis.

[30]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[31]  P. Gurbel,et al.  Assessment of oral antithrombotic therapy by platelet function testing , 2011, Nature Reviews Cardiology.

[32]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[33]  J. W. Schaeffer,et al.  ACC/AHA guidelines for the management of patients with unstable angina and non‐ST segment elevation myocardial infarction: Executive summary and recommendations , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[34]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[35]  J. Badimón,et al.  A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial , 2011, European heart journal.

[36]  E. Antman,et al.  Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 , 2008, Circulation.

[37]  M. Feuring,et al.  Coagulation status in coronary artery disease patients with type II diabetes mellitus compared with non-diabetic coronary artery disease patients using the PFA-100® and ROTEM® , 2010, Platelets.

[38]  G. Montalescot,et al.  Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study , 2008, Circulation.

[39]  Jeffrey L. Anderson,et al.  2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. , 2008, Journal of the American College of Cardiology.

[40]  P. Gurbel,et al.  Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. , 2009, The American journal of cardiology.

[41]  S. Manoukian.  Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. , 2009, The American journal of cardiology.

[42]  D. Angiolillo,et al.  Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.

[43]  J. Leonardi-Bee,et al.  Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke , 2006, Platelets.

[44]  C. Macaya,et al.  Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. , 2007, Journal of the American College of Cardiology.

[45]  W. Herzog,et al.  Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. , 2009, Journal of the American College of Cardiology.

[46]  Hani Jneid,et al.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.

[47]  P. Gurbel,et al.  Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. , 2010, American heart journal.

[48]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

[49]  D. Angiolillo,et al.  Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome , 2011, Circulation.

[50]  P. Gurbel,et al.  Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: Results of the Thrombotic RIsk Progression (TRIP) Study , 2010, Platelets.

[51]  Deepak L. Bhatt,et al.  Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. , 2002, The American journal of cardiology.